Regulation of inositol phosphate signaling pathways activity in patients with a poor ovarian response. Possibilities of adjuvant therapy
AbstractThe article provides information on inositol phosphate signaling pathways that act as key regulators of oocyte growth and maturation. The use of inositol phosphate messenger precursor molecules as a targeted adjuvant therapy in patients with poor ovarian response is discussed. The possibility of using methods for analyzing the metabolomic profile of follicular fluid to assess the effect of adjuvant therapy on folliculogenesis, quality of oocytes and embryos is being considered.
Keywords:IVF; assisted reproductive technologies; poor ovarian response; infertility; adjuvant therapy; signaling pathways; myoinositol; metabolomics
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
Contribution. Search and analysis of literature, processing of source material, writing the text of the manuscript – Zakovryashin E.A.; concept development, editing and final approval of the manuscript – Korneeva I.E.; editing and final approval of the manuscript – Mityurina E.V.
For citation: Zakovryashin E.A., Korneeva I.E., Mityurina E.V. Regulation of inositol phosphate signaling pathways activity in patients with a poor ovarian response. Possibilities of adjuvant therapy. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2024; 12 (1): 30–6. DOI: https://doi.org/10.33029/2303-9698-2024-12-1-30-36 (in Russian)
REFERENCES
1. Barrenetxea G., Hernández C., Herrero J., Martínez Navarro L., Muñoz M., Rubio J.M., et al. Use of gonadotropins in ovarian stimulation in Spain: Delphi consensus. J Obstet Gynaecol. 2023; 43 (1): 2174692.
2. Safdari-Dehcheshmeh F., Noroozi M., Taleghani F., Memar S. Factors influencing the delay in childbearing: a narrative review. Iran J Nurs Midwifery Res. 2023; 28 (1): 10–9.
3. Abu-Musa A., Haahr T., Humaidan P. Novel physiology and definition of poor ovarian response; clinical recommendations. Int J Mol Sci. 2020; 21 (6): 2110.
4. Esteves S.C., Yarali H., Vuong L.N., Conforti A., Humaidan P., Alviggi C. POSEIDON groups and their distinct reproductive outcomes: effectiveness and cost-effectiveness insights from real-world data research. Best Pract Res Clin Obstet Gynaecol. 2022; 85 (pt B): 159–87.
5. Roque M., Haahr T., Esteves S.C., Humaidan P. The POSEIDON stratification – moving from poor ovarian response to low prognosis. JBRA Assist Reprod. 2021; 25 (2): 282–92.
6. Orvieto R. Stop GnRH-agonist/GnRH-antagonist protocol: a different insight on ovarian stimulation for IVF. Reprod Biol Endocrinol. 2023; 21 (1): 13.
7. Jiao Z., Bukulmez O. Potential roles of experimental reproductive technologies in infertile women with diminished ovarian reserve. J Assist Reprod Genet. 2021; 38 (10): 2507–17.
8. Hsu C.C., Hsu I., Lee L.H., Hsu R., Hsueh Y.S., Lin C.Y., et al. Ovarian follicular growth through intermittent vaginal gonadotropin administration in diminished ovarian reserve women. Pharmaceutics. 2022; 14 (4): 869.
9. Zhu F., Yin S., Yang B., Li S., Feng X., Wang T., et al. TEAS, DHEA, CoQ10, and GH for poor ovarian response undergoing IVF-ET: a systematic review and network meta-analysis. Reprod Biol Endocrinol. 2023; 21 (1): 64.
10. Liao Z., Li Y., Li C., Bian X., Sun Q. Nuclear transfer improves the developmental potential of embryos derived from cytoplasmic deficient oocytes. iScience. 2023; 26 (8): 107299.
11. Tesarik J., Mendoza-Tesarik R. Mitochondria in human fertility and infertility. Int J Mol Sci. 2023; 24 (10): 8950.
12. Catandi G.D., Bresnahan D.R., Peters S.O., Fresa K.J., Maclellan L.J., Broeckling C.D., et al. Equine maternal aging affects the metabolomic profile of oocytes and follicular cells during different maturation time points. Front Cell Dev Biol. 2023; 11: 1239154.
13. Fontana J., Martínková S., Petr J., Žalmanová T., Trnka J. Metabolic cooperation in the ovarian follicle. Physiol Res. 2020; 69 (1): 33–48.
14. Pei Z., Deng K., Xu C., Zhang S. The molecular regulatory mechanisms of meiotic arrest and resumption in Oocyte development and maturation. Reprod Biol Endocrinol. 2023; 21 (1): 90.
15. Shi Y.Q., Zhu X.T., Zhang S.N., Ma Y.F., Han Y.H., Jiang Y., et al. Premature ovarian insufficiency: a review on the role of oxidative stress and the application of antioxidants. Front Endocrinol (Lausanne). 2023; 14: 1172481.
16. Wdowiak A., Filip M. The effect of myo-inositol, vitamin D3 and melatonin on the oocyte quality and pregnancy in in vitro fertilization: a randomized prospective controlled trial. Eur Rev Med Pharmacol Sci. 2020; 24 (16): 8529–36.
17. Canosa S., Paschero C., Carosso A., Leoncini S., Mercaldo N., Gennarelli G., et al. Effect of a combination of myo-inositol, alpha-lipoic acid, and folic acid on oocyte morphology and embryo morphokinetics in non-PCOS overweight/obese patients undergoing IVF: a pilot, prospective, randomized study. J Clin Med. 2020; 9 (9): 2949.
18. Mohammadi F., Ashrafi M., Zandieh Z., Najafi M., Niknafs B., Amjadi F.S., et al. The effect of preincubation time and myo-inositol supplementation on the quality of mouse MII oocytes. J Reprod Infertil. 2020; 21 (4): 259–68.
19. Merviel P., James P., Bouée S., Le Guillou M., Rince C., Nachtergaele C., et al. Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies. Reprod Health. 2021; 18 (1): 13.
20. Galatis D., Kalopita K., Grypiotis I., Flessas I., Kiriakopoulos N., Micha G. Researching the phenomenon of poor ovarian responders and management strategies in IVF: a narrative review. Acta Med Acad. 2022; 51 (2): 108–22.
21. Dinicola S., Unfer V., Facchinetti F., Soulage C.O., Greene N.D., Bizzarri M., et al. Inositols: from established knowledge to novel approaches. Int J Mol Sci. 2021; 22 (19): 10575.
22. Storey A., Elgmati K., Wang Y., Knaggs P., Swann K. The role of ATP in the differential ability of Sr2+ to trigger Ca2+ oscillations in mouse and human eggs. Mol Hum Reprod. 2021; 27 (1): gaaa086.
23. Tu-Sekine B., Kim S.F. The inositol phosphate system – a coordinator of metabolic adaptability. Int J Mol Sci. 2022; 23 (12): 6747.
24. Bizzarri M., Monti N., Piombarolo A., Angeloni A., Verna R. Myo-inositol and D-chiro-inositol as modulators of ovary steroidogenesis: a narrative review. Nutrients. 2023; 15 (8): 1875.
25. Sugimura S., Richani D., Gilchrist R.B. Follicular guidance for oocyte developmental competence. Anim Reprod. 2018; 15 (suppl 1): 721–5.
26. Oduwole O.O., Huhtaniemi I.T., Misrahi M. The roles of luteinizing hormone, follicle-stimulating hormone and testosterone in spermatogenesis and folliculogenesis revisited. Int J Mol Sci. 2021; 22 (23): 12735.
27. Recchia K., Jorge A.S., Pessôa L.V.F., Botigelli R.C., Zugaib V.C., de Souza A.F., et al. Actions and roles of FSH in germinative cells. Int J Mol Sci. 2021; 22 (18): 10110.
28. Chu Y.L., Xu Y.R., Yang W.X., Sun Y. The role of FSH and TGF-β superfamily in follicle atresia. Aging (Albany NY). 2018; 10 (3): 305–21.
29. Marchais M., Gilbert I., Bastien A., Macaulay A., Robert C. Mammalian cumulus-oocyte complex communication: a dialog through long and short distance messaging. J Assist Reprod Genet. 2022; 39 (5): 1011–25.
30. Artini P.G., Tatone C., Sperduti S., D’Aurora M., Franchi S., Di Emidio G., et al.; Italian Society of Embryology, Reproduction and Research (SIERR). Cumulus cells surrounding oocytes with high developmental competence exhibit down-regulation of phosphoinositol 1,3 kinase/protein kinase B (PI3K/AKT) signalling genes involved in proliferation and survival. Hum Reprod. 2017; 32 (12): 2474–84.
31. Ulloa-Aguirre A., Reiter E., Crépieux P. FSH receptor signaling: complexity of interactions and signal diversity. Endocrinology. 2018; 159 (8): 3020–35.
32. Kalous J., Aleshkina D., Anger M. A role of PI3K/Akt signaling in oocyte maturation and early embryo development. Cells. 2023; 12 (14): 1830.
33. Nagyová E., Němcová L., Camaioni A. Cumulus extracellular matrix is an important part of oocyte microenvironment in ovarian follicles: its remodeling and proteolytic degradation. Int J Mol Sci. 2021; 23 (1): 54.
34. Keeble S., Firman R.C., Sarver B.A.J., Clark N.L., Simmons L.W., Dean M.D. Evolutionary, proteomic, and experimental investigations suggest the extracellular matrix of cumulus cells mediates fertilization outcomes†. Biol Reprod. 2021; 105 (4): 1043–55.
35. Cantó C., Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol. 2009; 20 (2): 98–105.
36. Bang S., Kim S., Dailey M.J., Chen Y., Moran T.H., Snyder S.H., et al. AMP-activated protein kinase is physiologically regulated by inositol polyphosphate multikinase. Proc Natl Acad Sci USA. 2012; 109 (2): 616–20.
37. Lin Y., Huang Y., Li B., Zhang T., Niu Y., Hu S., et al. Novel mutations in PLCZ1 lead to early embryonic arrest as a male factor. Front Cell Dev Biol. 2023; 11: 1193248.
38. Kashir J., Ganesh D., Jones C., Coward K. Oocyte activation deficiency and assisted oocyte activation: mechanisms, obstacles and prospects for clinical application. Hum Reprod Open. 2022; 2022 (2): hoac003.
39. Uh K., Hay A., Chen P., Reese E., Lee K. Design of novel oocyte activation methods: the role of zinc. Biol Reprod. 2022; 106 (2): 264–73.
40. Yeste M., Jones C., Amdani S.N., Patel S., Coward K. Oocyte activation deficiency: a role for an oocyte contribution? Hum Reprod Update. 2016; 22 (1): 23–47.
41. Caprio F., D’Eufemia M.D., Trotta C., Campitiello M.R., Ianniello R., Mele D., et al. Myo-inositol therapy for poor-responders during IVF: a prospective controlled observational trial. J Ovarian Res. 2015; 8: 37.
42. Mohammadi S., Eini F., Bazarganipour F., Taghavi S.A., Kutenaee M.A. The effect of Myo-inositol on fertility rates in poor ovarian responder in women undergoing assisted reproductive technique: a randomized clinical trial. Reprod Biol Endocrinol. 2021; 19 (1): 61.
43. Viardot-Foucault V., Zhou J., Bi D., Takinami Y., Chan J.K.Y., Lee Y.H. Dehydroepiandrosterone supplementation and the impact of follicular fluid metabolome and cytokinome profiles in poor ovarian responders. J Ovarian Res. 2023; 16 (1): 107.
44. Bastos D.C.D.S., Chiamolera M.I., Silva R.E., Souza M.D.C.B., Antunes R.A., Souza M.M., et al. Metabolomic analysis of follicular fluid from women with Hashimoto thyroiditis. Sci Rep. 2023; 13 (1): 12497.
45. Liu A., Shen H., Li Q., He J., Wang B., Du W., et al. Determination of tryptophan and its indole metabolites in follicular fluid of women with diminished ovarian reserve. Sci Rep. 2023; 13 (1): 17124.
46. Li J., Zhang Z., Wei Y., Zhu P., Yin T., Wan Q. Metabonomic analysis of follicular fluid in patients with diminished ovarian reserve. Front Endocrinol (Lausanne). 2023; 14: 1132621.
47. Liang C., Zhang X., Qi C., Hu H., Zhang Q., Zhu X., et al. UHPLC-MS-MS analysis of oxylipins metabolomics components of follicular fluid in infertile individuals with diminished ovarian reserve. Reprod Biol Endocrinol. 2021; 19 (1): 143.
48. He F., Wang F., Yang Y., Yuan Z., Sun C., Zou H., et al. The effect of growth hormone on the metabolome of follicular fluid in patients with diminished ovarian reserve. Reprod Biol Endocrinol. 2023; 21 (1): 21.
49. Song H., Qin Q., Yuan C., Li H., Zhang F., Fan L. Metabolomic profiling
of poor ovarian response identifies potential predictive biomarkers. Front Endocrinol (Lausanne). 2021; 12: 774667.